Preferred Label : HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131;
NCIt synonyms : IMU-131 HER2/Neu Peptide Vaccine; HER-Vaxx; P467-CRM197/Montanide Vaccine IMU-131; IMU-131 Vaccine; HER-Vaxx Peptide Vaccine;
NCIt definition : A cancer vaccine consisting of a fusion peptide, composed of three peptides derived
from the extracellular domain (ECD) of the HER2 peptide antigen found on B-cells (P4,
P6 and P7; P467), conjugated to the carrier protein DT-CRM197, a non-toxic, mutated
form of diphtheria toxin (DT), and combined with the immunoadjuvant montanide ISA
51, with potential immunostimulatory and antineoplastic activities. Upon administration,
IMU-131 vaccine induces the production of polyclonal antibodies against the HER2 protein.
In turn, the antibodies bind to three separate binding sites on HER2 expressed on
tumor cells and inhibit HER2 dimerization and activity, which leads to the inhibition
of HER2-mediated signal transduction pathways. This induces apoptosis in and reduces
cellular proliferation of HER2-overexpressing tumor cells. In addition, IMU-131 induces
a cytotoxic T-lymphocyte (CTL) response against the HER2-expressing tumor cells. The
tumor-associated antigen (TAA) HER2, also called Neu or ErbB2, is a tyrosine kinase
receptor for epidermal growth factor (EGF) and is often overexpressed by a variety
of tumor cell types. Montanide ISA 51, also known as incomplete Freund's adjuvant
or IFA, is a stabilized water-in-oil (w/o) emulsion adjuvant containing mineral oil
with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated
immune responses to antigens. DT-CRM197 is used to increase the immunogenicity of
the HER2/neu peptide antigen. In P467, the three B-cell epitopes were combined in
a specific order into a single 49 amino acid peptide antigen.;
Molecule name : IMU-131;
NCI Metathesaurus CUI : CL507937;
Origin ID : C128283;
UMLS CUI : C4287755;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
